Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction

Annual Review of Immunology

Volumn 10, Issue , 1992, Pages 519-560

  Sigal, Nolan H ^a   Dumont, Francis J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cyclophilin; FKBP; immunosuppression; peptidyl prolyl cis trans isomerase; transplantation

Indexed keywords

CYCLOSPORIN; ISOMERASE; LYMPHOKINE; PROLINE; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; B LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0026748870     PISSN: 03013782     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.iy.10.040192.002511     Document Type: Review

References (186)

1. Borel, J. F., Feurer, C., Gubler, H. U., Stahelin, H. 1976. Biological effects of cyclosporin A: A new antilymphocyte agent. Agents Action 6: 468-75
2. Shevach, E. M. 1985. The effects of cyclosporin A on the immune system. Annu. Rev. Immunol. 3: 397-423
3. Borel, J. F. 1989. Pharmacology of cyclosporine (Sandimmune). IV. Pharmacological properties in vivo. Pharmacol. Rev. 41: 259-371
4. Mason, J. 1989. Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev. 41: 423-34
5. Kahan, B. D. 1989. Drug therapy. Cyclosporine. N. Engl. J. Med. 321: 1725-38
6. Masuda, K., Urayama, A., Kogure, M., Nakajima, A., Nakae, K., Inaba, G. 1989. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Bechet's disease. Lancet 1: 1093-95
7. Bougneres, P.-F., Landais, P., Boisson, C., Carel, J.-C., Frament, N., Boitard, C., Chaussain, J.-L., Bach, J.-F. 1990. Limited duration of remission of insulin dependency in children with recent overt type 1 diabetes treated with low dose cyclosporin. Diabetes 39: 1264-71
8. Ellis, C. N., Fradin, M. S., Messana, J. M., Brown, M. D., Siegel, M. T., Hartley, A. H., Rocher, L. L., Wheeler, S., Hamilton, T. A., Parish, T. G., Ellismadu, M., Duell, E., Annesley, T. M., Cooper, K. D., Voorhees, J. J. 1991. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N. Engl. J. Med. 324: 277-84
9. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H., Imanaka, H. 1987. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, physico-chemical and biological characteristics. J. Antibiot. 40: 1249-55
10. Thomson, A. W. 1990. FK-506 enters the clinic. Immunol. Today 11: 35-36
11. Fung, J. J., Todo, S., Tzakis, A., Alessiani, M., Abuelmagd, K., Jain, A., Bronster, O., Martin, M., Gordon, R., Starzl, T. E. 1991. Current status of FK-506 in liver transplantation. Transplant. Proc. 23: 1902-5
12. Armitage, J. M., Kormos, R. L., Griffith, B. P., Hardesty, R. L., Fricker, F. J., Stuart, R. S., Marrone, G. C., Todo, S., Fung, J., Starzl, T. E. 1991. A clinical trial of FK506 as primary and rescue immunosuppression in cardiac transplantation. Transplant. Proc. 23: 1149-52
13. Shapiro, R., Jordan, M., Fung, J., McCauley, J., Johnston, J., Iwaki, Y., Tzakis, A., Hakala, T., Todo, S., Starzl, T. E. 1991. Kidney transplantation under FK506 immunosuppression. Transplant. Proc. 23: 920-23
14. Starzl, T. E., Abuelmagd, K., Tzakis, A., Fung, J. J., Porter, K. A., Todo, S. 1991. Selected topics on FK506, with special references to rescue of extrahepatic whole organ grafts, transplantation of forbidden organs, side effects, mechanisms, and practical pharmacokinetics. Transplant. Proc. 23: 914-19
15. Vezina, C., Kudelski, A., Sehgal, S. N. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28: 721-26
16. Sehgal, S. N., Baker, H., Vezina, C. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28: 727-32
17. Martel, R. R., Klicius, J., Galet, S. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55: 48-51
18. Morris, R. E. 1991. Rapamycin: FK506's fraternal twin or distant cousin? Immunol. Today 12: 137-40
19. Calne, R. Y., Lim, S., Samaan, A., Collier, S. J., Pollard, S. G., White, D. J. G. 1989. Rapamycin for immunosuppression in organ allografting. Lancet 2: 227
20. Kahan, B. D., Gibbons, S., Tejpal, N., Stepkowski, S. M., Chou, T. C. 1991. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51: 232-39
21. Palestine, A. G., Austin, H. A., Brown, J. E., Antonovych, T. T., Sabnis, S. G., Preuss, H. G., Nussenblatt, R. B. 1986. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N. Engl. J. Med. 314: 1293-98
22. Shapiro, R., Fung, J. J., Jain, A. B., Parks, P., Todo, S., Starzl, T. E. 1990. The side effects of FK506 in humans. Transplant. Proc. 22: 35-36
23. Sawada, S., Suzuki, G., Kawase, Y., Takaku, F. 1987. Novel immunosuppressive agent, FK506. In vitro effects on cloned T cell activation. J. Immunol. 139: 1797-1803
24. Kay, J. E., Benzie, C. R., Goodier, M. R., Wick, C. J., Doe, S. E. 1989. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. Immunology 67: 473-77
25. Dumont, F. J., Staruch, M. J., Koprak, S. L., Melino, M. R., Sigal, N. H. 1990. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144: 251-58
26. Herold, K. C., Lancki, D. W., Moldwin, R. L., Fitch, F. W. 1986. Immunosuppressive effects of cyclosporin A on cloned T cells. J. Immunol. 136: 1315-21
27. Havele, C., Paetkau, V. 1988. Cyclosporine blocks the activation of antigen dependent cytotoxic T lymphocytes directly by an IL-2 independent mechanism. J. Immunol. 140: 3303-8
28. Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H., Ochiai, T. 1987. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 40: 1256-65
29. Yoshimura, N., Matsui, S., Hamashima, T., Oka, T. 1989. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 47: 351-56
30. Thomas, J., Matthews, C., Carroll, R., Loreth, R., Thomas, F. 1990. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. Transplantation 49: 390-96
31. June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T., Thompson, C. B. 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporin-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7: 4472-81
32. Kay, J. E., Benzie, C. R. 1989. T lymphocyte activation through the CD28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. Immunol. Lett. 23: 155-59
33. Lin, C. S., Boltz, R. C., Siekierka, J. J., Sigal, N. H. 1991. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell. Immunol. 133: 269-84
34. Bierer, B. E., Schreiber, S. L., Burakoff, S.-J. 1991. The effect of the immunosuppressant FK-506 on alternate pathways of T-cell activation. Eur. J. Immunol. 21: 439-45
35. Sigal, N. H., Lin, C. S., Siekierka, J. J. 1991. Inhibition of human T-cell activation by FK-506, rapamycin, and cyclosporine A. Transplant. Proc. 23: 1-5
36. Kay, J. E., Kromwel, L., Doe, S. E. A., Denyer, M. 1991. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72: 544-49
37. Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., Schreiber, S. L. 1990. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK-506 or rapamycin. Proc. Natl. Acad. Sci. USA 87: 9231-35
38. Kay, J. E., Benzie, C. R. 1984. Rapid loss of sensitivity of mitogen-induced lymphocyte activation to inhibition by cyclosporin A. Cell. Immunol. 87: 221-24
39. Eng, C. P., Sehgal, S. N., Vezina, C. 1984. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. 32: 1231-37
40. Kronke, M., Leonard, W. J., Depper, J. M., Arya, S. K., Wong-Staal, F., Gallo, R. C., Waldman, T. A., Greene, W. C. 1984. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc. Natl. Acad. Sci. USA 81: 5214-18
41. Granelli-Piperno, A. 1988. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J. Exp. Med. 168: 1649-58
42. Tocci, M. J., Matkovich, D. A., Collier, K. A., Kwok, P., Dumont, F., Lin, S., Degudicibus, S., Siekierka, J. J., Chin, J., Hutchinson, N. I. 1989. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 143: 718-26
43. Hess, A. D. 1985. Effect of interleukin 2 on the immunosuppressive action of cyclosporin. Transplantation 39: 62-68
44. Dumont, F. J., Altmeyer, A. 1990. Differential modulation of IL-1-induced IFN-γ production by the immunosuppressive macrolides rapamycin (RAP) and FK-506. Lymphokine Res. 9: 574
45. Granelli-Piperno, A. 1990. Lymphokine gene expression in vivo is inhibited by cyclosporin-A. J. Exp. Med. 171: 533-44
46. Kasaian, M. T., Biron, C. A. 1990. Cyclosporin-A inhibition of interleukin-2 gene expression, but not natural killer cell proliferation, after interferon induction in vivo. J. Exp. Med. 171: 745-62
47. Chisholm, P. M., Drayson, M. T., Cox, J. H., Ford, W. L. 1985. The effects of cyclosporin on lymphocyte activation in a systematic graft-vs-host reaction. Eur. J. Immunol. 15: 1054-58
48. Chisholm, P. M., Bevan, D. J. 1988. T cell activation in the presence of cyclosporine in three in vivo allograft models. Transplantation 46: 80S
49. Kroczek, R. A., Black, C. D. V., Barbet, J., Shevach, E. M. 1987. Mechanism of action of cyclosporin A in vivo I. Cyclosporin A fails to inhibit lymphocyte activation in response to alloantigens. J. Immunol. 139: 3597-3605
50. Pereira, G. M. B., Miller, J. F., Shevach, E. M. 1990. Mechanism of action of cyclosporine A in vivo II. T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyclosporine A-resistant pathway. J. Immunol. 144: 2109-16
51. Fujita, T., Shibuya, H., Ohashi, T., Yamanishi, K., Taniguchi, T. 1986. Regulation of human interleukin-2 gene: functional DNA sequences in the 5′ flanking region for the gene expression in activated T lymphocytes. Cell 46: 407-10
52. Durand, D. B., Bush, M. R., Morgan, J. G., Weiss, A., Crabtree, G. R. 1987. A 275 bp fragment at the 5′ end of the IL-2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor. J. Exp. Med. 165: 395-407
53. Ullman, K. S., Northrop, J. P., Verweij, C. L., Crabtree, G. R. 1990. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu. Rev. Immunol. 8: 421-52
54. Emmel, E. A., Verweij, C. L., Durand, D. B., Higgins, K. M., Lacy, E., Crabtree, G. R. 1989. Cyclosporin-A specifically inhibits function of nuclear proteins involved in T-cell activation. Science 246: 1617-20
55. Mattila, P. S., Ullman, K. S., Fiering, S., Emmel, E. A., McCutcheon, M., Crabtree, G. R., Herzenberg, L. A. 1990. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J. 9: 4425-33
56. Brabletz, T., Pietrowski, I., Serfling, E. 1991. The immunosuppressives FK-506 and cyclosporin-A inhibit the generation of protein factors binding to the 2 purine boxes of the interleukin-2 enhancer. Nucleic Acids Res. 19: 61-67
57. Banerji, S. S., Parsons, J. N., Tocci, M. J. 1991. The immunosuppressant, FK-506, specifically inhibits mitogen-induced activation of the IL-2 promoter and the isolated enhancer elements, NFIL-2A and NF-AT1. Mol. Cell. Biol. 11: 5074-87
58. Baumann, G., Geisse, S., Sullivan, M. 1991. Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. New Biol. 3: 270-78
59. Granelli-Piperno, A., Nolan, P., Inaba, K., Steinman, R. M. 1990. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J. Exp. Med. 172: 1869-72
60. Reed, J. Abidi, A., Alpers, J., Hoover, R., Robb, R., Nowell, P. 1986. Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J. Immunol. 137: 150-54
61. Lillehoj, H. S., Malek, T. R., Shevach, E. M. 1984. Differential effect of cyclosporin A on the expression of T and B lymphocyte activation antigens. J. Immunol. 133: 244-50
62. Ryffel, B., Tammi, K., Grieder, A., Hess, A. D. 1985. Effect of cyclosporine on human T cell activation. Transplant. Proc. 17: 1268-70
63. Foxwell, B., Simon, J., Herrero, J., Tay|or, D., Woerly, G., Ryffel, B. 1990. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A. Immunology 69: 104-9
64. Woo, J., Sewell, H. F., Thomson, A. W. 1990. The influence of FK-506 and low concentration cyclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytomeric analysis. Scand. J. Immunol. 31: 297-304
65. Hemar, A., Dautry-Varsat, A. 1990. Cyclosporin A inhibits the interleukin 2 receptor alpha chain gene transcription but not its cell surface expression. The alpha chain stability can explain this discrepancy. Eur. J. Immunol. 20: 2629-35
66. Malek, T. R., Ashwell, J. D. 1985. Interleukin 2 upregulates expression of its receptor on a T cell clone. J. Exp. Med. 161: 1575-80
67. Granelli-Piperno, A., Andrus, L., Steinman, R. M. 1986. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J. Exp. Med. 163: 922-37
68. Furue, M., Katz, S. I., Kawakami, Y., Kawakami, T. 1990. Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine. J. Immunol. 144: 736-39
69. Gunter, K. C., Irving, S. G., Zipfel, P. F., Siebenlist, U., Kelly, K. 1989. Cyclosporin A-mediated inhibition of mitogen-induced gene transcription is specific for the mitogenic stimulus and cell type. J. Immunol. 142: 3286-91
70. Bhat, N. K., Thompson, C. B., Lindstein, T., June, C. H., Fujiwara, S., Koizumi, S., Fischer, R. J., Papas, T. S. 1990. Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation. Regulatory role of the protooncogene ETS1. Proc. Natl. Acad. Sci. USA 87: 3723-27
71. Dumont, F. J., Staruch, M. J., Flattery, A., Altmeyer, A., Sigal, N. H. 1991. Upregulation of gene expression by FK-506. Transplant. Proc. In press
72. Altmeyer, A., Staruch, M. J., Fischer, P. A., Durette, P. L., Tocci, M. J., Sigal, N. H., Dumont, F. J. 1991. Unexpected up-regulation of gene expression by cyslosporine A and FK-506 in a T cell lymphoma: Both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. Int. J. Immunopharmacol. In press
73. Lancki, D., Kaper, B. P., Fitch, F. W. 1989. The requirements for triggering of lysis by cytolytic T lymphocyte clones. II. Cyclosporin A inhibits TCR-mediated exocytosis but only selectively inhibits TCR-mediated lytic activity by cloned CTL. J. Immunol. 142: 416-24
74. Trenn, G., Taffa, R., Hohman, R., Kincade, R., Shevach, E. M., Sitkovsky, M. 1989. Biochemical characterization of the inhibitory effect of CsA on cytolytic T-lymphocyte effector functions. J. Immunol. 42: 3796-3802
75. cεRI+ cells. J. Immunol. 146: 2374-81
76. Forrest, M. J., Jewell, M. E., Koo, G. C., Sigal, N. H. 1991. FK-506 and cyclosporin A: selective inhibition of calcium ionophore induced polymorphonuclear leukocyte degranulation. Biochem. Pharmacol. In press
77. Ucker, D. S., Ashwell, J. D., Nickas, G. 1989. Activation-driven T cell death. I. Requirements for de novo transcription and translation and association with genome fragmentation. J. Immunol. 143: 3461-68
78. Odaka, C., Kizaki, H., Tadakuma, T. 1990. T cell receptor-mediated DNA fragmentation and cell death in T cell hybridomas. J. Immunol. 144: 2096-2101
79. 2+ requirements and sensitivity to cyclosporine A. J. Immunol. 142: 4085-92
80. Shi, Y. F., Sahai, B. M., Green, D. R. 1989. Cyclosporin A inhibits activation-induced cell death in T cell hybridomas and thymocytes. Nature 339: 625-26
81. Staruch, M. J., Sigal, N. H., Dumont, F. J. 1991. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T cell apoptosis. Int. J. Immunopharmacol. 13: 677-85
82. Jenkinson, E. J., Kingston, R., Smith, C. A., Williams, G. T., Owen, J. J. T. 1989. Antigen-induced apoptosis in developing T cells: A mechanism for negative selection of the T cell receptor repertoire. Eur. J. Immunol. 19: 2175-77
83. Kappler, J. W., Roehm, N., Marrack, P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49: 273-80
84. Kosaka, H., Matsubara, H., Sogoh, S., Ogata, M., Hamaoka, T., Fujiwara, H. 1990. An in vitro model for cyclosporin A-induced interference of intrathymic clonal elimination. J. Exp. Med. 172: 395-98
85. Gao, E. K., Lo, D., Cheney, R., Kanagawa, O., Sprent, J. 1988. Abnormal differentiation of thymocytes in mice treated with cyclosporine A. Nature 336: 176-79
86. Jenkins, M. K., Schwartz, R. H., Pardoll, D. M. 1988. Effects of cyclosporin A on T cell development and clonal deletion. Science 241: 1655-58
87. Sakaguchi, S., Sakaguchi, N. 1988. Thymus and autoimmunity. Transplantation of the thymus from cyclosporin A-treated mice causes organ-specific autoimmune disease in athymic nude mice. J. Exp. Med. 167: 1479-87
88. Sakaguchi, S., Sakaguchi, N. 1989. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J. Immunol. 142: 471-80
89. Glazier, A., Tutschka, P. J., Farmer, E. R., Santos, G. W. 1983. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J. Exp. Med. 158: 1-8
90. Fischer, A. C., Hess, A. D. 1990. Age-related factors in cyclosporine-induced syngeneic graft-versus-host disease: regulatory role of marrow-derived T lymphocytes. J. Exp. Med. 172: 85-94
91. Bryson, J. S., Caywood, B. E., Kaplan, A. M. 1991. Relationship of cyclosporine A-mediated inhibition of clonal deletion and development syngeneic graft-versus-host disease. J. Immunol. 147: 391-97
92. Suzuki, N., Sakane, T., Tsunematsu, T. 1990. Effects of a novel immunosuppressive agent, FK506, on human B-cell activation. Clin. Exp. Immunol. 79: 240-45
93. Klaus, G. 1988. Cyclosporine-sensitive and cyclosporine-insensitive modes of B cell stimulation. Transplantation 46: 11S-14S
94. Walliser, P., Benzie, C. R., Kay, J. E. 1989. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. Immunology 68: 434-35
95. Wicker, L. S., Boltz, R. C., Matt, V., Nichols, E. A., Peterson, L. B., Sigal, N. H. 1990. Suppression of B-cell activation by cyclosporin-A, FK506 and rapamycin. Eur. J. Immunol. 20: 2277-83
96. Muraguchi, A., Butler, J. L., Kehrl, J. H., Falkoff, R. J. M., Fauci, A. S. 1983. Selective suppression of an early step in human B cell activation by cyclosporin A. J. Exp. Med. 158: 690-702
97. Hannam-Harris, A. C., Taylor, D. S., Nowell, P. C. 1985. Cyclosporin A directly inhibits human B cell activation by more than a single mechanism. J. Leuk. Biol. 38: 231-39
98. Benson, A., Ziegler, H. K. 1989. Macrophages as targets for inhibition by cyclosporine. Transplantation 47: 696-703
99. Granelli-Piperno, A., Keane, M., Steinman, R. M. 1988. Evidence that cyclosporin inhibits cell-mediated immunity primarily at the level of the T lymphocyte rather than the accessory cell. Transplantation 46: 53S-60S
100. Nguyen, D. T., Eskandari, M. K., Deforge, L. E., Raiford, C. L., Strieter, R. M., Kunkel, S. L., Remick, D. G. 1990. Cyclosporin A modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J. Immunol. 144: 3822-28
101. Palay, D. A., Cluff, C. W., Wentworth, P. A., Ziegler, H. K. 1986. Cyclosporine inhibits macrophage-mediated antigen presentation. J. Immunol. 136: 4348-53
102. Knight, S., Roberts, M., Macatonia, S., Edwards, A. 1988. Blocking of acquisition and presentation of antigen by dendritic cells with cyclosporine. Transplantation 46: 48S-53S
103. Muller, S., Adorini, L., Appella, E., Nagy, Z. A. 1988. Lack of influence of cyclosporine on antigen presentation to lysozyme-specific T cell hybridomas. Transplantation 46: 44S-48S
104. Little, R. G., Ebertowski, L. A., David, C. S. 1990. Inhibition of alloantigen presentation by cyclosporine. Transplantation 49: 937-44
105. Woo, J., Propper, D. J., Thomson, A. W. 1990. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. Immunology 71: 551-55
106. Marone, G., Triggiani, M., Cirillo, R., Giacummo, A., Siri, L., Condorelli, M. 1988. Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells. Ric. Clin. Lab. 18: 53-59
107. 2+ fluxes. J. Immunol. 144: 2659-64
108. Cirillo, R., Triggiani, M., Siri, L., Ciccarelli, A., Pettit, G. R., Condorelli, M., Marone, G. 1990. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J. Immunol. 144: 3891-97
109. Krensky, A. M., Weiss, A., Crabtree, G., Davis, M. M., Parham, P. 1990. T lymphocyte antigen interactions in transplant rejection. N. Engl. J. Med. 322: 510-17
110. Metcalfe, S. 1984. Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation 38: 161-64
111. Fidelus, R. K., Laughter, A. H. 1986. Protein kinase activation and the immunosuppressant cyclosporine. Transplantation 41: 187-92
112. Bijsterbosch, M. K., Klaus, G. G. B. 1985. Cyclosporin does not inhibit mitogen-induced inositol phospholipid degradation in mouse lymphocytes. Immunology 56: 435-40
113. Mizushima, Y., Kosaka, H., Sakuma, S., Kanda, K., Itoh, K., Osugi, T., Mizushima, A., Hamaoka, T., Yoshida, H., Sobue, K., Fujiwara, H. 1987. Cyclosporin A inhibits late steps of T lymphocyte activation after transmembrane signaling. J. Biochem. 102: 1193-1201
114. Fujii, Y., Fujii, S., Kaneko, T. 1989. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. Transplantation 47: 1081-83
115. Bierer, B. E., Schreiber, S. L., Burakoff, S. J. 1990. Mechanisms of immunosuppression by FK506. Preservation of T-cell transmembrane signal transduction. Transplantation 49: 1168-70
116. Zipfel, P. F., Irving, S. G., Kelley, K., Siebenlist, U. 1989. Complexity of the primary genetic response to mitogenic activation of human T cells. Molec. Cell. Biol. 9: 1041-48
117. Kwon, B. S., Weissman, S. M. 1989. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA 86: 1963-67
118. Wilkinson, M. F., MacLeod, C. L. 1988. Complex regulation of the T cell receptor alpha gene. Three different modes of triggering induction. Eur. J. Immunol. 18: 873-79
119. Dumont, F. J., Melino, M. R., Staruch, M. J., Koprak, S. L., Fischer, P. A., Sigal, N. H. 1990. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T-cells. J. Immunol. 144: 1418-24
120. Dumont, F. J., Fischer, P. A., Staruch, M. J., Sigal, N. H. 1990. Kinetic analysis of the reversal of FK-506-mediated immunosuppression by rapamycin. FASEB J. 4: A2038 (Abstr.)
121. Bierer, B. E., Somers, P. K., Wandless, T. J., Burakoff, S. J., Schreiber, S. L. 1990. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 250: 556-59
122. Handschumacher, R. E., Harding, M. W., Rice, J., Drugge, R. J., Speicher, D. W. 1984. Cyclophilin. A specific cyfosolic binding protein for cyclosporin A. Science 226: 544-47
123. Harrison, R. K., Stein, R. L. 1990. Substrate specificities of the peptidyl-prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein. Evidence for the existence of a family of distinct enzymes. Biochemistry 29: 3813-16
124. Kofron, J. L., Kuzmic, P., Kishore, V., Colon-Bonilla, E., Rich, D. H. 1991. Determination of kinetic constants for peptidyl-prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 30: 6127-34
125. Koletsky, A. J., Harding, M. W., Handschumacher, R. E. 1986. Cyclophilin. Distribution and variant properties in normal and neoplastic tissues. J. Immunol. 137: 1054-59
126. Haendler, B., Hofer, W. R., Hofer, E. 1987. Complementary DNA for human T-cell cyclophilin. EMBO J. 6: 947-50
127. Haendler, B., Keller, R., Hiestand, P. C., Kocher, H. P., Wegmann, G., Movva, N. R. 1989. Yeast cyclophilin. Isolation and characterization of the protein, cDNA and gene. Gene 83: 39-46
128. Liu, J., Albers, M. W., Chen, C. M., Schreiber, S. L., Walsh, C. T. 1990. Cloning, expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 87: 2304-8
129. Gasser, C. S., Gunning, D. A., Budelier, K. A., Brown, S. M. 1990. Structure and expression of cytosolic cyclophilin/peptidyl-prolyl cis-trans isomerase of higher plants and production of active tomato cyclophilin in Escherichia coli. Proc. Natl. Acad. Sci. USA 87: 9519-23
130. Tropschug, M., Nicholson, D. W., Hartl, F. U., Kohler, H., Pfanner, N., Wachter, E., Neupert, W. 1988. Cyclosporin A-binding protein (cyclophilin) of Neurospora crassa. One gene codes for both the cytosolic and mitochondrial forms. J. Biol. Chem. 263: 14433-40
131. Fischer, G., Wittmann, L. B., Lang, K., Kiefhaber, T., Schmid, F. X. 1989. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337: 476-78
132. Takahashi, N., Hayano, T., Suzuki, M. 1989. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 337: 473-75
133. Siekierka, J. J., Staruch, M. J., Hung, S. H., Sigal, N. H. 1989. FK-506, a potent novel immunosuppressiye agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J. Immunol. 143: 1580-83
134. Sierkierka, J. J., Hung, S. H., Poe, M., Lin, C. S., Sigal, N. H. 1989. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341: 755-57
135. Harding, M. W., Galat, A., Uehling, D. E., Schreiber, S. L. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341: 758-60
136. Standaert, R. F., Galat, A., Verdine, G. L., Schreiber, S. L. 1990. Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature 346: 671-74
137. Tropschug, M., Wachter, E., Mayer, S., Schonbrunner, E. R., Schmid, F. X. 1990. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. Nature 346: 674-77
138. Wiederrecht, G., Brizuela, L., Elliston, K., Sigal, N. H., Siekierka, J. J. 1991. FKBI encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. Proc. Natl. Acad. Sci. USA 88: 1029-33
139. Siekierka, J. J., Wiederrecht, G., Greulich, H., Boulton, D., Hung, S. H. Y., Cryan, J., Sigal, N. H. 1990. The cytosolic binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. J. Biol. Chem. 265: 21011-15
140. Fischer, G., Berger, E., Bang, H. 1989. Kinetic beta-deuterium isotope effects suggest a covalent mechanism for the protein folding enzyme peptidyl-prolyl cis/trans-isomerase. FEBS Lett. 250: 267-70
141. Lightowlers, M. W., Haralambous, A., Rickard, M. D. 1989. Amino acid sequence homology between cyclophilin and a cDNA-cloned antigen of Echinococcus granulosus. Mol. Biochem. Parasitol. 36: 287-89
142. Harrison, R. K., Stein, R. L. 1990. Mechanistic studies of peptidyl-prolyl cis-trans isomerase. Evidence for catalysis by distortion. Biochemistry 29: 1684-89
143. Rosen, M. K., Standaert, R. F., Galat, A., Nakatsuka, M., Schreiber, S. L. 1990. Inhibition of FKBP rotamase activity by the immunosuppressant FK506. Twisted amide surrogate. Science 248: 863-66
144. Albers, M. W., Walsh, C. T., Schreiber, S. L. 1990. Substrate specificity for the human rotamase FKBP. A view of FK506 and rapamycin as leucine-(twisted amide)-proline mimics. J. Org. Chem. 55: 4984-86
145. Fesik, S. W., Gampe, R. J., Holzman, T. F., Egan, D. A., Edalji, R., Luly, J. R., Simmer, R., Helfrich, R., Kishore, V., Rich, D. H. 1990. Isotope-edited NMR of cyclosporin A bound to cyclophilin. Evidence for a trans 9,10 amide bond. Science 250: 1406-9
146. Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S. L., Clardy, J. 1991. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 252: 839-42
147. Goebl, M. G. 1991. The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12-kD endogenous inhibitor-2 of protein kinase-C. Cell 64: 1051-52
148. Cryan, J., Hung, S. H. Y., Wiederrecht, G., Sigal, N. H., Siekierka, J. S. 1991. FKBP, the binding protein for the immunosuppressive drug FK-506, is not an inhibitor of protein kinase C activity. Biochem. Biophys. Res. Commun. 180: 846-52
149. Hayano, T., Takahashi, N., Kato, S., Maki, N., Suzuki, M. 1991. Two distinct forms of peptidyl-prolyl cis-trans isomerase are expressed separately in periplasmic and cytoplasmic compartments of Escherichia coli cells. Biochemistry 30: 3041-48
150. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J. 268: 153-60
151. Griffiths, E. J., Halestrap, A. P. 1991. Further evidence that cyclosporin-A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. Biochem. J. 274: 611-14
152. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem. J. 255: 357-60
153. Broekemeier, K. M., Pfeiffer, D. R. 1989. Cyclosporin A-sensitive and insensitive mechanisms produce the permeability transition in mitochondria. Biochem. Biophys. Res. Commun. 163: 561-66
154. Price, E. R., Zydowsky, L. D., Jin, M. J., Baker, C. H., McKeon, F. D., Walsh, C. T. 1991. Human cyclophilin B. A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc. Natl. Acad. Sci. USA 88: 1903-7
155. Koser, P. L., Sylvester, D., Livi, G. P., Bergsma, D. J. 1990. A second cyclophilin-related gene in Saccharomyces cerevisiae. Nucleic Acids Res. 18: 1643
156. Spik, G., Haendler, B., Delmas, O., Mariller, C., Chamoux, M., Maes, P., Tartar, A., Montreuil, J., Stedman, K., Kocher, H. P., Keller, R., Hiestand, P. C., Movva, N. R. 1991. A novel secreted cyclophilin-like protein (SCYLP). J. Biol. Chem. 266: 10735-38
157. Caroni, P., Rothenfluh, A., McGlynn, E., Schneider, C. 1991. S-Cyclophilin. New member of the cyclophilin family associated with the secretory pathway. J. Biol. Chem. 266: 10739-42
158. Shieh, B. H., Stamnes, M. A., Seavello, S., Harris, G. L., Zuker, C. S. 1989. The ninaA gene required for visual transduction in Drosophila encodes a homologue of cyclosporin A-binding protein. Nature 338: 67-70
159. Schneuwly, S., Shortridge, R. D., Larrivee, D. C., Ono, T., Ozaki, M., Pak, W. L. 1989. Drosophila ninaA gene encodes an eye-specific cyclophilin (cyclosporine A binding protein). Proc. Natl. Acad. Sci. USA 86: 5390-94
160. Stamnes, M. A., Shieh, B.-H., Chuman, L., Harris, G. L., Zuker, C. S. 1991. The cyclophilin homolog ninaA is a tissue-specific integral membrane protein required for the proper synthesis of a subset of Drosophila rhodopsins. Cell 65: 219-27
161. Fretz, H., Albers, M. W., Galat, A., Standaert, R. F., Lane, W. S., Burakoff, S. J., Bierer, B. E., Schreiber, S. L. 1991. Rapamycin and FK506 binding proteins (immunophilins). J. Am. Chem. Soc. 113: 1409-11
162. Palaszynski, E. W., Donnelly, J. G., Soldin, S. J. 1991. Purification and
163. Russell, D. H., Matrisian, L., Kibler, R., Larson, D. F., Poulos, B., Magun, B. - E. 1984. Prolactin receptors on human lymphocytes and their modulation by cyclosporine. Biochem. Biophys. Res. Commun. 121: 899-906
164. Hiestand, P. C., Mekler, P., Nordmann, G. A., Permmongkol, C. 1986. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc. Natl. Acad. Sci. USA 83: 2599-2603
165. Colombani, P. M., Robb, A., Hess, A. D. 1985. Cyclosporin A binding to calmodulin. A possible site of action on T lymphocytes. Science 228: 337-39
166. LeGrue, S. J., Turner, R., Weisbrodt, N., Dedman, J. R. 1986. Does the binding of cyclosporine to calmodulin result in immunosuppression? Science 234: 68-71
167. Hait, W. N., Stein, J. M., Koletsky, A. J., Harding, M. W., Handschumacher, R. E. 1989. Activity of cyclosporin A and a non-immunosuppressive cyclosporin against multidrug resistant leukemic cell lines. Cancer Commun. 1: 35-43
168. Foxwell, B. M. J., Mackie, A., Ling, V., Ryffel, B. 1989. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Molec. Pharmacol. 36: 543-46
169. Ziegler, K., Primmer, M. 1986. Identification of cyclosporin binding sites in rat liver plasma membranes, isolated hepatocytes, and hepatoma cells by photoaffinity labeling using [3H]cyclosporin-diaziridine. Biochim. Biophys. Acta 855: 147-56
170. Ziegler, K., Primmer, M., Fritzsch, G., Koepsell, H. 1990. Cyclosporin binding to a protein component of the renal Na+-D-glucose cotransporter. J. Biol. Chem. 265: 3270-77
171. Michnick, S. W., Rosen, M. K., Wandless, T. J., Karplus, M., Schreiber, S. L. 1991. Solution structure of FKBP: a rotamase enzyme and receptor for FK506 and rapamycin. Science 252: 836-39
172. Zurini, M., Kallen, J., Mikol, V., Pfluegl, G., Jansonius, J. N., Walkinshaw, M. D. 1990. Crystallisation and preliminary X-ray diffraction studies of cyclophilin-tetrapeptide and cyclophilin-cyclosporin complexes. FEBS Lett. 276: 63-66
173. Heald, S. L., Harding, M. W., Handschumacher, R. E., Armitage, I. M. 1990. 1H NMR studies on bovine cyclophilin. Preliminary structural characterization of its complex with cyclosporin A. Biochemistry 29: 4466-78
174. Liu, J., Walsh, C. T. 1990. Peptidyl-prolyl cis-trans isomerase from Escherichia coli. A periplasmic homolog of cyclophilin that is not inhibited by cyclosporin A. Proc. Natl. Acad. Sci. USA 87: 4028-32
175. Liu, J., Chen, C. M., Walsh, C. T. 1991. Human and Escherichia coli cyclophilins. Sensitivity to inhibition by the immunosuppressant cyclosporin-A correlates with a specific tryptophan residue. Biochemistry 30: 2306-10
176. Bossard, M. J., Koser, P. L., Brandt, M., Bergsma, D. J., Levy, M. A. 1991. A single TrpI21 to AlaI21 mutation in human cyclophilin alters cyclosporin-A affinity and peptidyl-prolyl isomerase activity. Biochem. Biophys. Res. Commun. 176: 1142-48
177. Tropschug, M., Barthelmess, I. B., Neupert, W. 1989. Sensitivity to cyclosporin A is mediated by cyclophilin in Neurospora crassa and Saccharomyces cerevisiae. Nature 342: 953-55
178. Heitman, J., Movva, N. R., Hiestand, P. C., Hall, M. N. 1991. FK-506 binding protein proline rotamase is a target for the immunosuppressive agent FK-506 in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 88: 1948-52
179. Koltin, Y., Faucette, L., Bergsma, D. J., Levy, M. A., Cafferkey, R., Koser, P. L., Johnson, R. K., Livi, G. P. 1991. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506 binding protein. Mol. Cell. Biol. 11: 1718-23
180. Brizuela, L., Chrebet, G., Bostian, K. A., Parent, S. A. 1991. Antifungal properties of the immunosuppressant FK-506. Identification of an FK-506 responsive yeast gene distinct from FKB1. Mol. Cell. Biol. 11: 4616-26
181. Quesniaux, V. F., Schreier, M. H., Wenger, R. M., Hiestand, P. C., Harding, M. W., Van, R. M. 1987. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur. J. Immunol. 17: 1359-65
182. Sigal, N. H., Dumont, F., Durette, P., Siekierka, J. J., Peterson, L., Rich, D. H., Dunlap, B. E., Staruch, M. J., Melino, M. R., Koprak, S. L., Williams, D., Witzel, B., Pisano, J. 1991. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J. Exp. Med. 173: 619-28
183. Brandl, C. J., Deber, C. M. 1986. Hypothesis about the function of membrane-buried proline residues in transport proteins. Proc. Natl. Acad. Sci. USA 83: 917-21
184. Friedman, J., Weissman, I. 1991. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA. Cell 66: 799-806
185. Liu, J., Farmer, J. D. Jr., Lane, W. S., Friedman, J., Weissman, I., Schreiber, S. L. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK-506 complexes. Cell 66: 807-15
186. Schreiber, S. L. 1991. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283-87